Citius announces resubmission of BLA to FDA forLYMPHIR

Citius Pharmaceuticals announced the resubmission of the Company’s Biologics License Application, or BLA, FDA for LYMPHIR, or denileukin diftitox, an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma, or CTCL, after at least one prior systemic therapy. The resubmission follows ongoing engagement with the FDA resulting from a Complete Response Letter received on July 28, 2023. Citius believes it has addressed enhanced product testing and additional manufacturing controls noted in the letter. There were no safety or efficacy issues cited and no additional trials required. Based on Center for Drug Evaluation and Research timelines, FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act date is expected within 30 days of resubmission.